Peptio

Retatrutide clinical trials: results and status in 2026

Seven retatrutide trials have published results, three in phase 3, all run by Eli Lilly: what each found, and what has not yet reported.

Peptio Research

On this page12

Seven retatrutide trials have published their primary results: three phase 3 trials, two phase 2 trials, a phase 1b trial, and a phase 1 single-dose study reported inside the paper that first described the molecule 1 2 3 4 5 6 7. Eli Lilly, which developed the drug, sponsored and funded all seven, and every one of them had a placebo arm 8 9 10 11 12 13 14.

No published result covers more than 80 weeks of treatment; the longest are TRIUMPH-1 and TRIUMPH-2, which both appeared on 29 September 2026 1 2. Everything they report is a measurement such as body weight, HbA1c or a pain score, read here from the published abstracts.

Apart from dulaglutide, a comparator arm in the phase 1b and phase 2 diabetes trials, no published trial has set retatrutide against another drug 6 5. The trials against tirzepatide and semaglutide have not reported 15 16. Neither has any trial of cardiovascular, kidney or liver outcomes, and the first of those is not due to complete before 2029 17 18.

The published trials side by side

Trial Phase Population Number Comparator Duration Primary endpoint Main result per arm, with placebo
TRIUMPH-1 1 8 3 Adults with obesity, without diabetes 2339 randomised Placebo 80 weeks Body weight (9 mg and 12 mg); knee osteoarthritis pain and sleep apnoea in subgroups; registry also lists body weight to week 104 in an extension subset, unpublished Weight -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) against -3.9%; treatment-regimen estimand
TRIUMPH-2 2 3 Adults with type 2 diabetes and a BMI of 27 or higher 1152 randomised Placebo 80 weeks Body weight (9 mg and 12 mg) Weight -11.9% (4 mg), -16.8% (9 mg), -18.8% (12 mg) against -5.1%; treatment-regimen estimand
TRANSCEND-T2D-1 3 3 Adults with type 2 diabetes managed by diet and exercise alone 537 randomised Placebo 40 weeks HbA1c HbA1c -1.69% (4 mg), -1.86% (9 mg), -1.94% (12 mg) against -0.81%; treatment-regimen estimand
Phase 2 obesity trial 4 2 Adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition 338 enrolled Placebo 48 weeks Body weight at 24 weeks At 24 weeks, weight -7.2% (1 mg), -12.9% (4 mg, two arms combined), -17.3% (8 mg, two arms combined), -17.5% (12 mg) against -1.6%; least-squares means, no estimand named
Phase 2 type 2 diabetes trial 5 2 Adults with type 2 diabetes on diet and exercise alone or metformin 281 randomised, 275 in the efficacy analyses Placebo and dulaglutide 1.5 mg Endpoints at 24 and 36 weeks HbA1c at 24 weeks HbA1c -2.02% (12 mg) against -0.01% with placebo and -1.41% with dulaglutide; least-squares means, no estimand named
Phase 1b trial 6 1b Adults with type 2 diabetes 72 enrolled Placebo and dulaglutide 1.5 mg 12 weeks Safety and tolerability Placebo-adjusted body weight change of up to -8.96 kg, in the highest-dose group
Phase 1 single-dose study 7 14 1 Healthy participants 45 enrolled Placebo Single doses Per the registry, serious adverse events judged related to the study drug No figures in the abstract

Doses are the maintenance dose each arm was assigned. Weight results are the mean percentage change in body weight from the start of the trial.

TRIUMPH-1: obesity without diabetes, 80 weeks

TRIUMPH-1, published in the New England Journal of Medicine, randomised 2339 adults with obesity and without diabetes to retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks 1. Its registry record gives an actual enrolment of 2,335; the figures here follow the paper 8.

The published abstract reports three pre-specified primary outcomes, each tested for the 9 mg and 12 mg arms against placebo: percentage change in body weight in everyone, knee osteoarthritis pain in a subgroup of 574 participants, and the severity of obstructive sleep apnoea in a subgroup of 243 1. The registry record lists a fourth, "Percent Change from Baseline in Body Weight in Participants in Extension Subset", with the time frame "Baseline, Week 104", and an arm named "Retatrutide Extension Period" 8. No result for that outcome has been published.

An estimand is a trial's stated rule for what it is estimating, including how it counts people who stop or change treatment. For weight, TRIUMPH-1 used the treatment-regimen estimand, which the paper equates with intention-to-treat: everyone is analysed in the arm they were randomised to, whether or not they kept taking the drug. On that basis, mean body weight changed by -17.6% with 4 mg, -23.7% with 9 mg and -25.0% with 12 mg, against -3.9% with placebo 1. The differences from placebo were -19.8 percentage points for 9 mg and -21.0 for 12 mg; the abstract gives no difference for 4 mg 1.

For the two subgroup outcomes, the paper's main analysis used a hybrid estimand, applying in its words "a hypothetical strategy for intercurrent events suggesting treatment failure", and it also reports intention-to-treat results 1.

In the 574 participants with knee osteoarthritis, pain on the WOMAC scale, which the abstract describes as ranging from 1 to 10, changed under the hybrid estimand by -3.2, -3.5 and -3.6 points in the 4 mg, 9 mg and 12 mg arms, against -1.9 with placebo 1. The differences from placebo were -1.6 points for 9 mg and -1.8 for 12 mg 1. Under intention-to-treat the changes were -3.4, -3.9 and -4.1 against -2.5 with placebo, differences of -1.4 and -1.6 points 1. Pain improved in the placebo arm too, which is why the differences, not the raw changes, are the comparison the trial was built to make.

In the 243 participants with sleep apnoea, the apnoea-hypopnoea index, a count of breathing interruptions per hour of sleep, changed under intention-to-treat by -22.8, -34.3 and -32.1 events per hour in the 4 mg, 9 mg and 12 mg arms, against -9.6 with placebo 1. The differences from placebo were -24.7 for 9 mg and -22.5 for 12 mg 1. Under the hybrid estimand the stated differences were -24.4 and -21.9, against a placebo change of -9.9 1. The PubMed abstract prints the 12 mg arm's hybrid value without its minus sign 1. The dedicated sleep apnoea paper, published in October 2026, gives the hybrid values as -22.9, -34.3 and -31.7 events per hour, against -9.9 with placebo, from a baseline mean of 58.6 19. Its differences from placebo were -13.0 (95% confidence interval -23.0 to -3.0), -24.4 (-34.1 to -14.7) and -21.9 (-32.2 to -11.5), and under intention-to-treat the 4 mg difference was -13.2 19.

On adverse events the abstract says only: "The most common adverse events were gastrointestinal." It gives no frequencies and no discontinuation rate 1.

TRIUMPH-2: type 2 diabetes and a BMI of 27 or higher, 80 weeks

TRIUMPH-2, published in The Lancet, enrolled adults with type 2 diabetes, a body-mass index (BMI) of 27 or higher, and an HbA1c of 6.5% to 10.5% 2. HbA1c, glycated haemoglobin, is a blood measure of longer-term glucose control, reported as a percentage. The trial randomised 1152 people at 92 centres in eight countries: 292 to 4 mg, 284 to 9 mg, 287 to 12 mg and 289 to placebo 2. Their mean age was 55.1 years, and 554 (48%) were female 2. 1055 (92%) of 1152 participants were on any oral glucose-lowering medication 2.

The primary endpoint was percentage change in body weight at week 80 for 9 mg and 12 mg against placebo, with 4 mg against placebo a key secondary endpoint 2. Under the treatment-regimen estimand, with missing data imputed, mean body weight at week 80 changed by -11.9% with 4 mg, -16.8% with 9 mg and -18.8% with 12 mg, against -5.1% with placebo 2.

The estimated differences from placebo were -6.9 percentage points with 4 mg (95% confidence interval -8.7 to -5.1), -11.8 with 9 mg (-13.7 to -9.8) and -13.8 with 12 mg (-15.8 to -11.8) 2. The paper gives p<0.0001 for all three comparisons 2. 965 of the 1152 participants (84%) completed the study drug 2.

Weight fell less at each dose than in TRIUMPH-1, which enrolled people without diabetes 1 2. Diabetes is not the only difference: most TRIUMPH-2 participants were also taking glucose-lowering medication 2. The two were separate trials, and were not designed to be compared with each other.

The abstract leaves out three things a reader might expect. It gives no result under the efficacy estimand. It gives no figure for HbA1c, saying only that retatrutide was "associated with improvements in glycaemic control". And it does not report the sleep apnoea sub-study, although the registry record lists the apnoea-hypopnoea index as a primary outcome 2 9.

That sub-study was published separately in October 2026, together with the TRIUMPH-1 one 19. It randomised 448 adults with type 2 diabetes and moderate to severe sleep apnoea, with a baseline mean of 55.9 events per hour 19. At 80 weeks, under the hybrid-treatment estimand, the apnoea-hypopnoea index changed by -19.2 with 4 mg, -24.7 with 9 mg and -25.4 with 12 mg, against -10.3 with placebo 19. The differences from placebo were -8.9 (95% confidence interval -15.9 to -2.0), -14.4 (-21.6 to -7.2) and -15.1 (-22.5 to -7.7) 19. Under intention-to-treat they were -8.8, -13.9 and -15.0 19. The abstract names gastrointestinal events as the most common adverse events and gives no frequencies 19.

TRANSCEND-T2D-1: type 2 diabetes on diet and exercise, 40 weeks

TRANSCEND-T2D-1, published in The Lancet in June 2026, randomised 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone, with an HbA1c between 7.0% and 9.5% and a BMI of at least 23; their mean duration of diabetes was 2.5 years 3. It ran at 48 sites in the USA, Mexico and India, and assigned 134 people to 4 mg, 133 to 9 mg, 136 to 12 mg and 134 to placebo 3. The primary endpoint was change in HbA1c over 40 weeks 3.

Under the treatment-regimen estimand, mean HbA1c changed by -1.69% with 4 mg, -1.86% with 9 mg and -1.94% with 12 mg, against -0.81% with placebo 3. Because HbA1c is itself a percentage, these are changes in percentage points, not relative falls. The differences from placebo were -0.88 percentage points (95% confidence interval -1.18 to -0.59), -1.04 (-1.32 to -0.76) and -1.12 (-1.39 to -0.85) 3.

Body weight, a key secondary endpoint, changed by -11.5% with 4 mg, -13.9% with 9 mg and -15.3% with 12 mg, against -2.6% with placebo 3. The abstract does not restate which estimand those weight figures use, and gives no weight differences from placebo 3. 490 participants (91%) completed the treatment period on study drug and 504 (94%) completed the study 3.

The phase 2 trials

Both phase 2 trials report least-squares means, model-adjusted averages, and neither abstract names an estimand, so their figures are not directly comparable with the phase 3 results above 4 5. Both have results posted on ClinicalTrials.gov, the only retatrutide trials that do 11 12.

Obesity

The phase 2 obesity trial, published in the New England Journal of Medicine, enrolled 338 adults, 51.8% of them men, with a BMI of 30 or higher, or of 27 to under 30 with at least one weight-related condition 4. They were assigned to retatrutide at 1, 4, 8 or 12 mg, or to placebo, for 48 weeks; 4 mg and 8 mg were each given to two arms, which the paper reports combined 4. The primary endpoint was percentage change in body weight at 24 weeks 4.

At 24 weeks, body weight had changed by -7.2% with 1 mg, -12.9% with 4 mg, -17.3% with 8 mg and -17.5% with 12 mg, against -1.6% with placebo 4. At 48 weeks the changes were -8.7%, -17.1%, -22.8% and -24.2%, against -2.1% 4. If you have seen 24.2% quoted for retatrutide, this is where it comes from: the 12 mg arm of this trial at 48 weeks, with placebo at -2.1% 4.

By 48 weeks, 15% or more of body weight had been lost by 60% of the 4 mg group, 75% of the 8 mg group and 83% of the 12 mg group, against 2% of the placebo group 4.

Type 2 diabetes

The phase 2 type 2 diabetes trial, published in The Lancet, randomised 281 adults aged 18 to 75 at 42 centres in the USA, with an HbA1c of 7.0% to 10.5% and a BMI of 25 to 50 5. They were treated with diet and exercise alone or with metformin. They were assigned to placebo, to dulaglutide 1.5 mg as an active comparator, or to retatrutide at maintenance doses of 0.5, 4, 8 or 12 mg, with 4 mg and 8 mg each given to two arms 5. The primary endpoint was change in HbA1c at 24 weeks, with HbA1c and body weight at 36 weeks among the secondary endpoints; 275 participants were included in the efficacy analyses 5.

At 24 weeks, HbA1c in the 12 mg arm had changed by -2.02%, against -0.01% with placebo and -1.41% with dulaglutide 5. HbA1c fell significantly more than with placebo in every retatrutide arm except 0.5 mg, and significantly more than with dulaglutide in two arms, the 12 mg arm and one of the two 8 mg arms 5. At 36 weeks, body weight in the 12 mg arm had fallen by 16.94%, against 3.00% with placebo and 2.02% with dulaglutide 5.

This trial's population differs from TRANSCEND-T2D-1's; notably, it also enrolled people taking metformin 5 3.

Pre-specified substudies

Liver fat. 98 participants in the obesity trial who had MASLD (metabolic dysfunction-associated steatotic liver disease, fat build-up in the liver linked to metabolic conditions) and liver fat of at least 10% were randomised to retatrutide at 1, 4, 8 or 12 mg, or to placebo 21. At 24 weeks, the primary endpoint, liver fat had changed relative to its starting level by -42.9%, -57.0%, -81.4% and -82.4% in the four arms, against +0.3% with placebo 21. Liver fat fell into the normal range, below 5%, in 27%, 52%, 79% and 86% of the four arms, and in 0% of the placebo arm 21. Liver fat is a surrogate measure: the substudy reports nothing on fibrosis, liver tissue or clinical liver events, and its abstract names no estimand.

Body composition. A substudy of the diabetes trial enrolled 189 participants. 155 had a baseline DXA scan (dual-energy X-ray absorptiometry, which separates fat from lean tissue), and 103 completed treatment with scans at baseline and week 36 22. Total fat mass fell by 4.9% with 0.5 mg, 15.2% with 4 mg (arms pooled), 26.1% with 8 mg (pooled) and 23.2% with 12 mg, against 2.6% with dulaglutide and 4.5% with placebo 22. The differences from placebo were -0.4 percentage points for 0.5 mg (95% confidence interval -4.0 to 3.2, p=0.83), -10.7 for 4 mg, pooled (-17.2 to -4.2), -21.6 for 8 mg, pooled (-27.1 to -16.1), and -18.7 for 12 mg (-25.1 to -12.3) 22. The confidence interval for 0.5 mg includes zero 22. The analysis used data from participants while they were still on the study drug, which asks what happens in people who keep taking it rather than in everyone randomised. The abstract gives no lean-mass figure. On lean mass it says only: "The proportion of lean mass loss to weight loss was similar to other obesity treatments." 22

Appetite. Pre-specified exploratory analyses of the diabetes trial measured appetite and eating behaviour by questionnaire at 24 and 36 weeks 23. At week 24, participants on 4 mg or more reported greater reductions than with placebo in overall appetite, hunger and prospective food consumption; the differences against dulaglutide were less consistent 23. These are self-reports.

Later and secondary analyses

Several later papers return to the phase 2 trials. All are Lilly-authored, and none adds a new placebo-controlled primary result.

A kidney analysis, post hoc, meaning it was not specified before the data were seen, drew on both phase 2 trials 24. In participants with type 2 diabetes, 12 mg was associated with a change in urine albumin-to-creatinine ratio (UACR, a measure of protein leaking into the urine) of -37.0% against placebo at 36 weeks (95% confidence interval -57.3 to -7.0) 24. In that group, estimated glomerular filtration rate (eGFR, a measure of kidney function) was unchanged against placebo 24. In participants with overweight or obesity, 8 mg and 12 mg were associated at 48 weeks with changes in UACR of -28.0% (95% confidence interval -46.0 to -4.1) and -31.5% (-49.3 to -7.4) against placebo 24. In the same group, creatinine-based eGFR was higher than with placebo at 48 weeks, by 5.3 ml/min per 1.73 m² with 8 mg (95% confidence interval 1.9 to 8.7) and 8.5 ml/min per 1.73 m² with 12 mg (4.9 to 12.1) 24. The authors note that most participants had normal albuminuria, so the absolute reduction in UACR was modest 24.

A letter reporting secondary analyses of eating behaviour in the obesity trial found larger falls in self-reported disinhibition and perceived hunger with every retatrutide dose than with placebo at weeks 24 and 48 25. Cognitive restraint "significantly increased from baseline in all treatment groups", placebo included, and did not differ significantly between retatrutide and placebo 25. Only the letter's correlations with weight change are labelled post hoc, and its per-arm values appear in a figure 25. A qualitative interview study spoke to 40 participants as they left the same trial, only 4 of whom had received placebo, so it records experiences rather than measuring an effect 26.

The phase 1 studies

The phase 1b trial, published in The Lancet, enrolled 72 adults with type 2 diabetes, who all received at least one dose and were included in the safety analyses 6. Its primary purpose was to examine safety and tolerability over 12 weeks, against placebo and dulaglutide 1.5 mg 6. Placebo-adjusted weight reduction appeared to be dose dependent, reaching -8.96 kg (90% confidence interval -11.16 to -6.75) in the highest-dose group at 12 weeks 6. The half-life of retatrutide was approximately 6 days 6.

The earlier single ascending dose study, in 45 healthy participants, is reported inside the discovery paper rather than separately 14 7. Its abstract gives no numbers. It says that in this study retatrutide "showed a safety and tolerability profile similar to other incretins", and that "a reduction in body weight persisted up to day 43 after a single dose" 7. The registry record gives its primary outcome as the "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration" 14.

Adverse events across the trials

Trial Gastrointestinal events Other events reported Stopping treatment or completing it Deaths
TRIUMPH-1 1 The most common adverse events; no frequencies in the abstract None with frequencies in the abstract Not given in the abstract Not given in the sources used here
TRIUMPH-2 2 Diarrhoea 27%, 34%, 34% (4, 9, 12 mg) against 13%; nausea 14%, 21%, 28% against 8% Hypotension 1%, 5%, 6% against under 1%; dysesthesia 4%, 6%, 7% against 1% Stopped for adverse events or death: 4%, 12%, 8% against 5% 2, 3 and 1 against 1; all judged unrelated to the study intervention by the investigator
TRANSCEND-T2D-1 3 The most frequent; generally mild to moderate, and subsided over time No severe hypoglycaemia Stopped for adverse events: 2 to 5% against 0% 2, both in the 4 mg arm, unrelated to the study drug
Phase 2 obesity 4 11 The most common; dose-related, mostly mild to moderate Heart rate rose with dose, peaked at 24 weeks and declined thereafter Not given in the abstract Registry: 1, in one of the 4 mg arms; attribution not given in the sources used here
Phase 2 type 2 diabetes 5 35% across the retatrutide arms, from 13% to 50% by arm, against 13% with placebo and 35% with dulaglutide No severe hypoglycaemia 222 (79%) completed study treatment None
Phase 1b 6 The most frequently reported events Any treatment-emergent event: 33 (63%) on retatrutide, 3 of 5 on dulaglutide, 8 of 15 on placebo 29 left the study early; reasons not in the abstract Not given in the abstract

TRIUMPH-2 gives the most detail. Diarrhoea occurred in 80 of 292 participants on 4 mg, 95 of 284 on 9 mg and 96 of 286 on 12 mg, against 38 of 287 on placebo 2. Hypotension (low blood pressure) and dysesthesia (abnormal skin sensation) were both more frequent with retatrutide than with placebo 2. The abstract does not describe how severe either was.

Permanent discontinuation in TRIUMPH-2 was 11 (4%) with 4 mg, 33 (12%) with 9 mg and 22 (8%) with 12 mg, against 14 (5%) with placebo, and that figure counts adverse events and deaths together 2. It is higher at 9 mg than at 12 mg, so it does not rise steadily with dose 2. Two participants died in the 4 mg arm, three in the 9 mg arm, one in the 12 mg arm and one in the placebo arm, and the investigator judged every death unrelated to the study intervention 2.

In TRANSCEND-T2D-1, 2 to 5% of participants on retatrutide stopped the study drug because of adverse events, against 0% on placebo, and the two deaths, both in the 4 mg arm, were judged unrelated to the study drug 3. In the phase 2 diabetes trial, gastrointestinal events were reported by 67 of 190 participants on retatrutide (35%), ranging from 6 of 47 (13%) on 0.5 mg to 12 of 24 (50%) in one of the 8 mg arms, against 6 of 45 (13%) on placebo and 16 of 46 (35%) on dulaglutide 5. That trial reported no severe hypoglycaemia and no deaths 5.

The phase 2 obesity trial reported a dose-dependent rise in heart rate that peaked at 24 weeks 4. Its abstract does not say by how many beats per minute.

Past primary completion, no results published

Four larger trials have passed their primary completion date with neither a results publication nor results posted on ClinicalTrials.gov 20 27 28 16. This article uses only peer-reviewed publications and registry records, so no figure from any other report of these trials appears here. Where a Lilly announcement of a result was opened for this article, the trial's entry says so, without the figures.

TRIUMPH-4 is a phase 3 trial of 445 adults with obesity or overweight and knee osteoarthritis, against placebo 20. Its primary endpoints are WOMAC pain and percentage change in body weight at week 68 20. It is recorded as completed, with primary completion on 14 November 2025 20. In a press release of 11 December 2025, Lilly said that "each dose of retatrutide (9 mg and 12 mg) met all primary and key secondary endpoints", and that detailed results will be presented at a future medical meeting and published in a peer-reviewed journal 29. None of its figures is used here.

TRIUMPH-3 is a phase 3 trial of 1,946 adults with severe obesity and established cardiovascular disease, against placebo 27. Its primary endpoint is percentage change in body weight at week 80, not cardiovascular events 27. It is recorded as completed, with primary completion on 16 April 2026 27. In a press release of 23 July 2026, Lilly said that retatrutide "met the primary endpoint" in TRIUMPH-3, and that detailed results "will be presented at future medical meetings" 30. That is the sponsor's summary of an unpublished trial, and none of its figures is used here.

TRANSCEND-CKD is a phase 2b trial in adults with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, randomised 1 to retatrutide or placebo 28 31. Its primary endpoint is the change in measured glomerular filtration rate, by iohexol clearance, at week 24 31. It is recorded as completed, with primary completion on 1 October 2025 28. Only its design and baseline paper has been published: 146 of 367 people screened were randomised, with a mean age of 65.1 years and a mean measured filtration rate of 49.3 mL/min/1.73 m², and 37.7% had type 2 diabetes 31. That paper contains no outcome result.

TRANSCEND-T2D-2 is an open-label phase 3 trial comparing retatrutide with semaglutide in adults with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor 16. Its primary endpoint is HbA1c at week 80 and its estimated enrolment is 1,250 16. Its primary completion date of 27 August 2026 is recorded as actual, its status is active, not recruiting, and it has posted no results 16.

Twelve completed phase 1 studies, covering Japanese and Chinese participants, kidney and liver impairment, drug interactions, a radiolabelled disposition study, two bioavailability studies, oral contraceptive and metoprolol interactions, energy intake and expenditure, and the response to low blood glucose, have no results publication that could be found by searching PubMed for their registry numbers 32 33 34 35 36 37 38 39 40 41 42 43. That is not proof that none exists: one retatrutide paper with no abstract and no registry link may report one of them.

Still running

The head-to-head trials. TRIUMPH-5 randomises adults with obesity to retatrutide or tirzepatide, with percentage change in body weight at week 80 as its primary endpoint 15. It has an estimated enrolment of 800 and an estimated primary completion of November 2026 15. TRANSCEND-T2D-2, against semaglutide, is described above. Until one of them publishes, any claim that retatrutide does better than either drug rests on comparing arms from different trials. A 2025 systematic review of placebo-controlled obesity drug trials, which searched to 4 October 2024, recorded among its limitations: "No head-to-head RCTs were available." 44

The outcomes trials. TRIUMPH-Outcomes randomises an estimated 10,000 adults with a BMI of 27 or higher and atherosclerotic cardiovascular disease, chronic kidney disease or both, against placebo 17. Its primary endpoints are time to a major adverse cardiovascular event and time to a kidney composite outcome, over up to about 248 weeks, with an estimated primary completion of February 2029 17. SYNERGY-Outcomes, a master protocol that also covers tirzepatide, is recruiting an estimated 4,500 people with MASLD at risk of liver outcomes, against placebo 18. Its primary endpoint is time to major adverse liver outcomes, over up to about 224 weeks, with an estimated primary completion of August 2030 18.

Maintenance. TRIUMPH-6 is designed around keeping weight off, with a placebo switch arm. It has an estimated enrolment of 643, percentage change in body weight at week 116 as its primary endpoint, and an estimated primary completion of April 2028 45.

The rest, all active and no longer recruiting except the last:

Trial Phase Population Comparator Estimated enrolment Primary endpoint Estimated primary completion
TRANSCEND-T2D-3 46 3 Type 2 diabetes with moderate or severe kidney impairment, on basal insulin Placebo 320 HbA1c at week 52 October 2026
Insulin secretion study 47 1 Type 2 diabetes Semaglutide and placebo 95 Clamp disposition index at week 28 December 2026
TRIUMPH-8 48 3b Obesity or overweight without type 2 diabetes Placebo 250 Body weight at week 56 July 2027
TRIUMPH-7 49 3 Obesity or overweight with chronic low back pain Placebo 586 Pain score and body weight, up to 72 weeks September 2027
TRIUMPH-9 50 3b Obesity or overweight without type 2 diabetes Different dosing schemes of retatrutide; no placebo 600 Body weight at week 104 October 2028
Phase 2 obesity trial 51 2 Obesity Placebo 300 Body weight at week 24 14 March 2027

The last of these is recruiting, and is the only registered retatrutide trial whose sponsor is not Eli Lilly. Its record lists single masking, although its brief summary says double-blind, and types its placebo arm as experimental 51.

What the meta-analyses add

Little that is independent. None of the systematic reviews or meta-analyses read for this article reports including a phase 3 retatrutide result, and one of them does not state its search date, so every pooled retatrutide estimate rests on the phase 1b and phase 2 trials described above 52 53 54 55 56 57. The first phase 3 paper, TRANSCEND-T2D-1, appeared in June 2026 3.

Their pooled figures are not repeated here. None can be tied to an arm, a duration and a population the way a trial result can, and every one is built from the trials already described above. What each review pooled, and the direction it reported:

  • One included three studies comprising 640 patients, 510 of them given retatrutide, and reported lower body weight than with placebo 52. Its authors add that "Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term" 52.
  • Another pooled three randomised controlled trials against placebo, searched until May 2024, and reported lower body weight, BMI, waist circumference, fasting glucose, HbA1c and blood pressure 55. Its abstract does not name the trials, and the patient total it gives could not be reconciled with the published trials 55. The full text was not available.
  • A systematic review without a pooled estimate, searched until 15 March 2025, counted 691 randomised participants across three articles, 510 of them given retatrutide and 130 placebo 56. It found the largest reductions in body weight, BMI and waist circumference at 12 mg, and gastrointestinal effects the most commonly reported 56.
  • A fourth, whose abstract does not state how many trials it pooled, reported lower systolic blood pressure and no significant effect on HDL cholesterol 54.

They disagree about adverse events, four against two. One reports "an increase in non-severe gastrointestinal and hypersensitivity adverse events" 52. A multi-drug review reports: "Retatrutide had the highest AE risk." 58 Another finds that "retatrutide and cotadutide were associated with comparatively lower tolerability", while concluding that the leading drugs it ranked had "acceptable safety" 59. A fourth reports that "Low certainty evidence suggested higher rates for discontinuing treatment with danuglipron and retatrutide" 57. On the other side, one concludes: "The safety profile of retatrutide was found to be comparable to the control group." 53 And one found no significant difference in adverse events, with a relative risk of 1.11 (P = 0.24) 55. None of these abstracts gives a hypersensitivity count, and they measure different things: any adverse event, tolerability, or stopping treatment.

One pooled analysis reports HbA1c falling more at lower doses than at higher ones 60. That runs against the dose pattern in TRANSCEND-T2D-1 and the phase 2 diabetes trial 3 5. It is not without precedent, though. In the 12-week phase 1b trial, of the two highest dose groups, the higher showed the smaller placebo-adjusted fall in HbA1c: -1.2% (90% confidence interval -2.05 to -0.45) against -1.6% (-2.37 to -0.75), with intervals that overlap widely 6. The pooled analysis's full text, with the list of studies it included, could not be retrieved, so it is cited here as a conflict, not as a result.

Network meta-analyses rank many drugs at once by comparing them indirectly through shared comparators such as placebo, and they are where most comparisons with tirzepatide come from. One analysed 58 trials, limited to adults with overweight or obesity, to interventions of at least 12 weeks and to trials without participants with diabetes, and searched to 6 March 2026 57. On those terms the only published retatrutide trial that appears eligible is the phase 2 obesity trial, so its retatrutide estimate is that single 48-week trial seen through a different method 57 4. Its authors note that "confidence intervals overlapped for several comparisons" 57.

What these trials do not tell you

Whether retatrutide changes outcomes. Every published endpoint is a measurement: body weight, HbA1c, liver fat, a pain score, an apnoea index. None counts heart attacks, strokes, kidney failure, liver events or deaths as its endpoint. The trials built to do that have estimated primary completions of February 2029 and August 2030 17 18. The liver substudy measured fat, not liver tissue 21. The only trial with a kidney-function primary endpoint has published baseline data alone, and the kidney analysis that has been published was post hoc, in participants most of whom had normal albuminuria 31 24.

Anything beyond 80 weeks. No published result covers more than 80 weeks 1 2. TRIUMPH-1 itself registered a week-104 body weight outcome in an extension subset, and that result has not been published 8. Registered treatment periods also run to 104 weeks in TRIUMPH-9 and 116 weeks in TRIUMPH-6, and neither has reported 50 45. What happens to weight after stopping has not been published.

Independent replication. Every published trial was funded by Eli Lilly, and every substudy and post hoc analysis is Lilly-authored 1 2 3 4 5 24 25. The meta-analyses are not independent of that, because they pool the same trials.

The full papers. Every figure here was read from published abstracts and registry records. The full texts were not available, and they may carry what the abstracts leave out: adverse event frequencies for TRIUMPH-1, results under the efficacy estimand, the size of the heart rate increase, and lean mass.

Anything about products sold outside trials. Every result above describes Lilly's investigational product, given under trial conditions. None describes a product bought online. Whether such products contain what their labels say is a separate question, covered on the retatrutide page.

Peptides covered

Research areas

Sources

  1. 1. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. PubMed 42814954
  2. 2. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026. PubMed 42810372
  3. 3. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026. PubMed 42250575
  4. 4. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed 37366315
  5. 5. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023. PubMed 37385280
  6. 6. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022. PubMed 36354040
  7. 7. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. PubMed 35985340
  8. 8. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1). ClinicalTrials.gov. 2026. NCT05929066(open access)
  9. 9. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2). ClinicalTrials.gov. 2026. NCT05929079(open access)
  10. 10. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1). ClinicalTrials.gov. 2026. NCT06354660(open access)
  11. 11. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov. 2026. NCT04881760(open access)
  12. 12. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. ClinicalTrials.gov. 2026. NCT04867785(open access)
  13. 13. A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2026. NCT04143802(open access)
  14. 14. A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects. ClinicalTrials.gov. 2026. NCT03841630(open access)
  15. 15. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. 2026. NCT06662383(open access)
  16. 16. A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). ClinicalTrials.gov. 2026. NCT06260722(open access)
  17. 17. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). ClinicalTrials.gov. 2026. NCT06383390(open access)
  18. 18. A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes). ClinicalTrials.gov. 2026. NCT07165028(open access)
  19. 19. Grunstein RR et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. The New England Journal of Medicine. 2026. PubMed 42904878
  20. 20. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). ClinicalTrials.gov. 2026. NCT05931367(open access)
  21. 21. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. PubMed 38858523(open access)
  22. 22. Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. 2025. PubMed 40609566
  23. 23. Kanu C et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes, Obesity and Metabolism. 2025. PubMed 40916752(open access)
  24. 24. Heerspink HJL et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports. 2025. PubMed 40630318(open access)
  25. 25. Kanu C et al. Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. PubMed 40735804(open access)
  26. 26. Goetz IA et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars. 2025. PubMed 41216380(open access)
  27. 27. A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov. 2026. NCT05882045(open access)
  28. 28. A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. ClinicalTrials.gov. 2025. NCT05936151(open access)
  29. 29. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Eli Lilly and Company (press release, PR Newswire). 2025. View source(open access)
  30. 30. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Eli Lilly and Company (press release, PR Newswire). 2026. View source(open access)
  31. 31. Heerspink HJL et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2026. PubMed 41160422(open access)
  32. 32. A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2022. NCT04823208(open access)
  33. 33. A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943. ClinicalTrials.gov. 2023. NCT05548231(open access)
  34. 34. A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants. ClinicalTrials.gov. 2023. NCT05611957(open access)
  35. 35. A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants. ClinicalTrials.gov. 2025. NCT05916560(open access)
  36. 36. A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes. ClinicalTrials.gov. 2023. NCT05445232(open access)
  37. 37. Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants. ClinicalTrials.gov. 2023. NCT05757531(open access)
  38. 38. A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants. ClinicalTrials.gov. 2024. NCT06003465(open access)
  39. 39. Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index. ClinicalTrials.gov. 2024. NCT05959096(open access)
  40. 40. A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants. ClinicalTrials.gov. 2024. NCT06039826(open access)
  41. 41. A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants. ClinicalTrials.gov. 2025. NCT06808802(open access)
  42. 42. A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction. ClinicalTrials.gov. 2025. NCT06313528(open access)
  43. 43. A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia. ClinicalTrials.gov. 2026. NCT06982846(open access)
  44. 44. Moiz A et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials. Annals of Internal Medicine. 2025. PubMed 39761578
  45. 45. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6). ClinicalTrials.gov. 2026. NCT06859268(open access)
  46. 46. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3). ClinicalTrials.gov. 2026. NCT06297603(open access)
  47. 47. A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus. ClinicalTrials.gov. 2026. NCT06982859(open access)
  48. 48. A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-8). ClinicalTrials.gov. 2026. NCT07232719(open access)
  49. 49. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7). ClinicalTrials.gov. 2026. NCT07035093(open access)
  50. 50. A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial (TRIUMPH-9). ClinicalTrials.gov. 2026. NCT07357415(open access)
  51. 51. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov. 2026. NCT07467447(open access)
  52. 52. Pasqualotto E et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024. PubMed 39318607(open access)
  53. 53. Tewari J et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2025. PubMed 39817343
  54. 54. Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Pressure & Cardiovascular Prevention. 2026. PubMed 42371360
  55. 55. Abdrabou Abouelmagd A et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University Medical Center). 2025. PubMed 40291085
  56. 56. Misra S, Narayan RK, Kaur M. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of Basic and Clinical Physiology and Pharmacology. 2025. PubMed 40728138
  57. 57. Chen D et al. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Medicine. 2026. PubMed 42688617
  58. 58. Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity. 2025. PubMed 40685589
  59. 59. Abulehia A et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026. PubMed 41787737
  60. 60. Pallavi K et al. Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. Maedica. 2025. PubMed 41537067